BACKGROUND The role of intravenous immunoglobulin (IVIG) as an adjunctive treatment for severe sepsis remains controversial. We hypothesized that IVIG could be effective for treating pneumonia patients who have septic shock. METHODS Mechanically ventilated pneumonia patients with septic shock were identified in the nationwide Japanese Diagnosis Procedure Combination inpatient database from 1 ...

plasma cell differentiation [3-8]. IVIg also modulates cell-mediated immunity. It inhibits production of interleukin-2 and interferon-gamma by T cells, induces degradation of complement factors, and upregulates/downregulates expression of the FcγRII macrophage receptor [9-11]. An elegant experiment by Zhang et al. [12] revealed additional protective mechanisms of IVIg. The binding of mice anti-...

OBJECTIVE We wished to investigate whether increased IgG infusion rates are associated with metabolic and hematologic changes in pediatric patients with antibody deficiency syndromes. METHODS We studied 7 patients (2-16 years old) with primary antibody deficiencies who had been on regular IgG replacement treatment, 350-600 mg/kg/dose every 3 weeks with a 3% IVIG preparation, for periods rangi...

HSV-1 is the leading cause of sporadic encephalitis in humans. HSV infection of susceptible 129S6 mice results in fatal encephalitis (HSE) caused by massive inflammatory brainstem lesions comprising monocytes and neutrophils. During infection with pathogenic microorganisms or autoimmune disease, IgGs induce proinflammatory responses and recruit innate effector cells. In contrast, high dose intr...

Background: In refractory epilepsy patients with possible autoimmune-associated (AAE) but negative antibody testing(-AB), immunotherapy trials (IMT) may still be pursued.The value of in such remains unclear. For this reason, we reviewed their responses. Methods: Retrospective review admitted to the Epilepsy Unit between (2018-2021) who received (IMT). All had (-AB) and (methylprednisolone (IVMP...

Abstract Background Intravenous immunoglobulins (IVIG) therapy is increasingly used in the treatment of various paediatric diseases. Data about frequency and underlying mechanisms IVIG-related adverse events (IVIG-AEs) children are limited. Objectives this study were to document incidence IVIG-AEs hospitalized patients identify risk factors for IVIG-AEs. Design/Methods In retrospective cohort s...

We treated five consecutive patients with multifocal motor neuropathy (MMN) with high-dose intravenous immunoglobulin (IVIg). Four patients had increased levels of anti-asialo-GM1 IgM and two of anti-GM1 IgM as well; one patient had no reactivity. We treated them twice with 0.4 g/kg IVIg for 5 consecutive days at a 2-month interval, followed by maintenance infusions up to 6 to 12 months. All pa...

OBJECTIVE The purpose of this study was to compare the efficacy and side effects of intravenous immunoglobulin (IVIG) with intravenous anti-D immunoglobulin for treatment of newly diagnosed acute childhood Idiopathic thrombocytopenic purpura (ITP). METHODS Children (6 months to 14 years) with newly diagnosed acute ITP and platelet count below 20,000/ microL were randomized to receive single d...

High-dose i.v. Ig (IVIg) is a prominent immunomodulatory therapy for various autoimmune and inflammatory diseases. Recent mice studies suggest that IVIg inhibits myeloid cell function by inducing a cascade of IL-33-Th2 cytokine production causing upregulation of the inhibitory FcγRIIb, as well as by modulating IFN-γ signaling. The purpose of our study was to explore whether and how these mechan...

Cutaneous lupus erythematosus (CLE) is a chronic inflammatory autoimmune skin disease. Evidence-based therapy for CLE is lacking in the most part. Intravenous immunoglobulin (IVIg) is being increasingly utilized as off-label therapy for a variety of autoimmune and inflammatory conditions, especially in dermatology. The usefulness of IVIg in CLE is not well established. The goal of the present s...